Author
Listed:
- Stanley Zhou
(University Health Network
University of Toronto)
- James R. Hawley
(University Health Network
University of Toronto)
- Fraser Soares
(University Health Network)
- Giacomo Grillo
(University Health Network)
- Mona Teng
(University Health Network
University of Toronto)
- Seyed Ali Madani Tonekaboni
(University Health Network
University of Toronto)
- Junjie Tony Hua
(University Health Network
University of Toronto)
- Ken J. Kron
(University Health Network)
- Parisa Mazrooei
(University Health Network
University of Toronto)
- Musaddeque Ahmed
(University Health Network)
- Christopher Arlidge
(University Health Network)
- Hwa Young Yun
(University Health Network)
- Julie Livingstone
(Ontario Institute for Cancer Research)
- Vincent Huang
(Ontario Institute for Cancer Research)
- Takafumi N. Yamaguchi
(Ontario Institute for Cancer Research)
- Shadrielle M. G. Espiritu
(Ontario Institute for Cancer Research)
- Yanyun Zhu
(the Netherlands Cancer Institute)
- Tesa M. Severson
(the Netherlands Cancer Institute)
- Alex Murison
(University Health Network)
- Sarina Cameron
(University Health Network)
- Wilbert Zwart
(the Netherlands Cancer Institute
Eindhoven University of Technology)
- Theodorus Kwast
(University of Toronto)
- Trevor J. Pugh
(University Health Network
University of Toronto
Ontario Institute for Cancer Research)
- Michael Fraser
(Ontario Institute for Cancer Research)
- Paul C. Boutros
(University of Toronto
Ontario Institute for Cancer Research
University of Toronto
University of California)
- Robert G. Bristow
(University Health Network
University of Toronto
University of Toronto
CRUK Manchester Institute and Manchester Cancer Research Centre)
- Housheng Hansen He
(University Health Network
University of Toronto)
- Mathieu Lupien
(University Health Network
University of Toronto
Ontario Institute for Cancer Research)
Abstract
Prostate cancer is the second most commonly diagnosed malignancy among men worldwide. Recurrently mutated in primary and metastatic prostate tumors, FOXA1 encodes a pioneer transcription factor involved in disease onset and progression through both androgen receptor-dependent and androgen receptor-independent mechanisms. Despite its oncogenic properties however, the regulation of FOXA1 expression remains unknown. Here, we identify a set of six cis-regulatory elements in the FOXA1 regulatory plexus harboring somatic single-nucleotide variants in primary prostate tumors. We find that deletion and repression of these cis-regulatory elements significantly decreases FOXA1 expression and prostate cancer cell growth. Six of the ten single-nucleotide variants mapping to FOXA1 regulatory plexus significantly alter the transactivation potential of cis-regulatory elements by modulating the binding of transcription factors. Collectively, our results identify cis-regulatory elements within the FOXA1 plexus mutated in primary prostate tumors as potential targets for therapeutic intervention.
Suggested Citation
Stanley Zhou & James R. Hawley & Fraser Soares & Giacomo Grillo & Mona Teng & Seyed Ali Madani Tonekaboni & Junjie Tony Hua & Ken J. Kron & Parisa Mazrooei & Musaddeque Ahmed & Christopher Arlidge & H, 2020.
"Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer,"
Nature Communications, Nature, vol. 11(1), pages 1-13, December.
Handle:
RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-14318-9
DOI: 10.1038/s41467-020-14318-9
Download full text from publisher
Citations
Citations are extracted by the
CitEc Project, subscribe to its
RSS feed for this item.
Cited by:
- Alexandros Armaos & François Serra & Iker Núñez-Carpintero & Ji-Heui Seo & Sylvan C. Baca & Stefano Gustincich & Alfonso Valencia & Matthew L. Freedman & Davide Cirillo & Claudia Giambartolomei & Gian, 2023.
"The PENGUIN approach to reconstruct protein interactions at enhancer-promoter regions and its application to prostate cancer,"
Nature Communications, Nature, vol. 14(1), pages 1-17, December.
- Jeroen Kneppers & Tesa M. Severson & Joseph C. Siefert & Pieter Schol & Stacey E. P. Joosten & Ivan Pak Lok Yu & Chia-Chi Flora Huang & Tunç Morova & Umut Berkay Altıntaş & Claudia Giambartolomei & Ji, 2022.
"Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential,"
Nature Communications, Nature, vol. 13(1), pages 1-16, December.
- Roberta Esposito & Andrés Lanzós & Tina Uroda & Sunandini Ramnarayanan & Isabel Büchi & Taisia Polidori & Hugo Guillen-Ramirez & Ante Mihaljevic & Bernard Mefi Merlin & Lia Mela & Eugenio Zoni & Lusin, 2023.
"Tumour mutations in long noncoding RNAs enhance cell fitness,"
Nature Communications, Nature, vol. 14(1), pages 1-21, December.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-14318-9. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.